117
Participants
Start Date
April 12, 2021
Primary Completion Date
March 31, 2024
Study Completion Date
May 31, 2024
LUT014 Gel (Dose 1)
Topical gel
LUT014 Gel (Dose 2)
Topical gel
Placebo
LUT014 matching placebo topical gel
RECRUITING
Memorial Sloane Kettering, New York
RECRUITING
New York Cancer and Blood Specialists, New York
RECRUITING
UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
Miami Dermatology & Laser Research, Miami
RECRUITING
Miami Dermatology and Laser Institute, Miami
RECRUITING
Moffit Cancer Center, Tampa
RECRUITING
Appalachian Regional Healthcare, Hazard
RECRUITING
The Christ Hospital, Cincinnati
RECRUITING
Willis-Knighton Cancer Center, Shreveport
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
UCLA, Santa Monica
RECRUITING
Innovative Clinical Research Institute, Glendale
NOT_YET_RECRUITING
Providence Regional Cancer Partnership, Everett
RECRUITING
MultiCare Institute for Research and Innovation, Tacoma
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Hackensack Meridian Health, Neptune City
RECRUITING
Assuta Ashdod, Ashdod
RECRUITING
E. Wolfson Medical Center, Holon
RECRUITING
Shaara Zedek Medical Center, Jerusalem
Lead Sponsor
Lutris Pharma Ltd.
INDUSTRY